TP-1287

TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active CDK9 inhibitor[1].

Product Specifications

CAS Number

[2044686-42-0]

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tp-1287.html

Purity

95.10

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C) |Methanol : 125 mg/mL (ultrasonic)

Smiles

O=P(O)(O)OC1=CC(O)=C(C(C=C(C2=C(C=CC=C2)Cl)O3)=O)C3=C1[C@@H]4[C@@H](CN(CC4)C)O

Molecular Formula

C21H21ClNO8P

Molecular Weight

481.82

References & Citations

[1]Tyagi E, et al. The Oral CDK9 Inhibitor, TP-1287, Is Active in Non-Clinical Models of Multiple Myeloma. Blood, 2018, 132: 3269.|[2]Kim W, et al. TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib. Cancer Research, 2017, 77 (13_Supplement) : 5133-5133.